Storage and transfusion of infected autologous blood or components: A survey of North American laboratories

Archives of Pathology and Laboratory Medicine

Volumn 129, Issue 8, 2005, Pages 981-983

  Shulman, Ira A ^a,b   Osby, Melanie ^c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b LAC USC MEDICAL CENTER   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; BLOOD AUTOTRANSFUSION; BLOOD COMPONENT THERAPY; BLOOD DONOR; BLOOD STORAGE; BLOOD TRANSFUSION; HEALTH SURVEY; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MAJOR CLINICAL STUDY; REVIEW; RISK ASSESSMENT;

BLOOD BANKS; BLOOD DONORS; BLOOD PRESERVATION; BLOOD TRANSFUSION, AUTOLOGOUS; DATA COLLECTION; HUMANS; LABORATORIES, HOSPITAL; MASS SCREENING; NORTH AMERICA; VIRUS DISEASES;

EID: 23044479250     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Bierbaum BE, Callaghan JJ, Galante JO, Rubash HE. An analysis of blood management in patients having total hip or knee arthroplasty. J Bone J Surg Am. 1999;81:2-10.
2. Downes KA, Yomtovian R. Advances in pre-transfusion infectious disease testing: assuring the safety of transfusion therapy. Clin Lab Med. 2002;22:475-490.
3. Dodd RY, Notari EP IV, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion. 2002;42:975-979.
4. Busch MP. HIV, HBV and HCV: new developments related to transfusion safety. Vox Sang. 2000;78(suppl 2):253-256.
5. Testing Requirements for Communicable Disease Agents. Food and Drug Administration (Subpart E), HHS (2003) (codified at 21 CFR §610.40).
6. Additional Standards for Human Blood and Blood Products, Subpart A-Whole Blood; Testing the Blood. Food and Drug Administration, HHS (2003) (codified at 21 CFR §640.5(a)).
7. Testing Requirements for Communicable Disease Agents. Food and Drug Administration (Subpart E), HHS (2003) (codified at 21 CFR §610.40(d)(1)).
8. Testing Requirements for Communicable Disease Agents. Food and Drug Administration (Subpart E), HHS (2003) (codified at 21 CFR §610.40(d)(2)).
9. Testing Requirements for Communicable Disease Agents. Food and Drug Administration (Subpart E), HHS (2003) (codified at 21 CFR §610.40(d)(3)).
10. Testing Requirements for Communicable Disease Agents. Food and Drug Administration (Subpart E), HHS (2003) (codified at 21 CFR §610.40(e)(1,2)) .
11. Shulman IA. 7992 CAP Surveys: Comprehensive Transfusion Medicine Survey, 1992 Set J-C. Northfield, III: Interlaboratory Comparison Program, College of American Pathologists; 1992.
12. Pub L No. 101-336, 104 Stat 327 (1990) (codified at 42 USC §12101-12213).
13. Bragdon v Abbott, 118 S Ct 2196 (1998). Available at: http://www.law. uh.edu/healthlawperspectives/Disabilities/980626Bragdon.html. Accessed March 31, 2005.
14. Legal Information Institute. Bragdon v Abbott (97-156), Syllabus. Available at: http://supct.law.cornell.edu/supct/html/97-156.ZS.html. Accessed March 31, 2005.
15. Mintz PD. Participation of HIV-infected patients in autologous blood programs. JAMA. 1993;269:2892-2894.
16. Yomtovian R, Kelly C, Bracey AW, et al. Procurement and transfusion of human immunodeficiency virus-positive or untested autologous blood units: issues and concerns: a report prepared by the Autologous Transfusion Committee of the American Association of Blood Banks. Transfusion. 1995;35:353-361.
17. The ADA, HIV, and Autologous Blood Donation. Bethesda, Md: American Association of Blood Banks; 1998. Association Bulletin 98-5.
18. Linden JV, Wagner K, Voytovich AE, Sheehan J. Transfusion errors in New York State: an analysis of 10 years' experience. Transfusion. 2000;40:1207-1213.